Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 671061, 6 pages
Clinical Study

IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain
2Rheumatology Division, Hospital Lucus Augusti, 27003 Lugo, Spain
3Endocrinology Division, Hospital Clínico Universitario, 47005 Valladolid, Spain
4Oncology Division, Hospital Del Bierzo, Ponferrada, 24411 León, Spain
5Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, IDIVAL and CIBER Epidemiología y Salud Pública (CIBERESP), 39011 Santander, Spain
6Cardiology Division, Hospital Lucus Augusti, 27003 Lugo, Spain
7Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa

Received 9 July 2014; Accepted 20 August 2014; Published 11 September 2014

Academic Editor: Patrick H. Dessein

Copyright © 2014 Fernanda Genre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Like rheumatoid arthritis, ankylosing spondylitis (AS) is also an inflammatory disease associated with accelerated atherosclerosis and the presence of metabolic syndrome (MeS) features. AS patients often display osteoporosis as well as new bone formation. Insulin-like growth factor 1 (IGF-1) is a protein involved in both inflammation and bone metabolism. In the present study we assessed whether disease activity, systemic inflammation, MeS features, adipokines, and biomarkers of endothelial activation were associated with IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) levels in a series of 30 nondiabetic AS patients without CV disease undergoing TNF- antagonist-infliximab therapy. All determinations were made in the fasting state, immediately before an infliximab infusion. Although no association of IGF-1 and IGFBP-3 levels with angiopoietin-2 or osteopontin was found, an inverse correlation between IGF-1 levels and asymmetric dimethylarginine (ADMA), an endogenous endothelial nitric oxide synthase inhibitor that impairs nitric oxide production and secretion promoting endothelial dysfunction, was found (; ). However, no significant association was found between IGF-1 and IGFBP-3 levels and disease activity, systemic inflammation, metabolic syndrome features, or adipokines. In conclusion, in nondiabetic patients with AS undergoing periodic anti-TNF- therapy, IGF-1 and ADMA are inversely correlated.